Press Releases

AiCuris Anti-infective Cures AG and the German Center for Infection Research (DZIF) have announced the signing of a collaboration and license option agreement today. As part of the collaboration, DZIF

BioVersys AG, a multi-asset, clinical stage biopharmaceutical company focusing on research and development of novel antibacterial products for serious life-threatening infections caused by multi-drug

Study shows efficacy and safety of oral antibiotic therapy in the form of pills for Staphylococcus aureus bloodstream infections. Currently, infusions are the standard treatment / published in ‘The

Tuberculosis is currently the infectious disease that causes the most deaths worldwide. Of particular concern is the increasing emergence of multidrug-resistant tuberculosis bacteria, particularly in

Bacteria that are resistant to broad-spectrum antibiotics from the carbapenem group are increasingly posing major problems for healthcare systems worldwide. They can cause serious infections and

Darobactin is a promising candidate for the development of new, resistance-breaking antibiotics, as it has an exceptional mechanism of action and a broad spectrum of activity. In a recent study, DZIF

INCATE, the INCubator for Antibacterial Therapies in Europe, and BIOASTER, the French Technology Research Institute, have announced this week the beginning of a new partnership that aims to improve

From 18 to 24 November, the “World AMR Awareness Week” (WAAW), a global campaign proclaimed by WHO, aims to draw attention to the near-pandemic rise in infections caused by resistant microbial

Despite decades of research, there is still no vaccine that protects against HIV infection. It is currently assumed, however, that such a vaccine can only be effective if it also produces so-called

With one of the highest tuberculosis (TB) incidences (368 cases/100,000 population) in the African region, Mozambique is particularly affected by the TB epidemic. Drug-resistant TB is also a major